You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR EQUETRO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for EQUETRO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00181870 ↗ Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder Completed Shire Phase 4 2005-07-01 This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. The main goal of this study is to begin to address the void of information on safety, tolerability and effectiveness of Equetro in the treatment of Pediatric Bipolar Disorder.
NCT00181870 ↗ Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder Completed Massachusetts General Hospital Phase 4 2005-07-01 This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. The main goal of this study is to begin to address the void of information on safety, tolerability and effectiveness of Equetro in the treatment of Pediatric Bipolar Disorder.
NCT00203567 ↗ Carbamazepine Extended-Release for the Treatment of Bipolar Depression Completed Shire Phase 4 2005-08-01 To study the efficacy and safety of beaded extended-release Carbamazepine (Equetro) in the treatment of patients with Bipolar Disorder with a Major Depressive Episode.
NCT00203567 ↗ Carbamazepine Extended-Release for the Treatment of Bipolar Depression Completed Tuscaloosa Research & Education Advancement Corporation Phase 4 2005-08-01 To study the efficacy and safety of beaded extended-release Carbamazepine (Equetro) in the treatment of patients with Bipolar Disorder with a Major Depressive Episode.
NCT00325286 ↗ Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Unknown status Shire Phase 4 2006-05-01 This is an open label design using Lithium plus extended release carbamazepine (Equetro) in combination for 6 months. Rapid cycling bipolar disorder is frequently treatment refractory and associated with repeated hospitalizations and complications. The results of this study will offer a promising approach to treat this complex disorder. The primary efficacy measure will be the time to relapse. Relapse will determined by the investigator based on the following: Need for additional pharmacotherapy for mood-related symptoms, hospitalization for an mood episode, increase of more than 50% in HAM-D and YMRS scores from the baseline visit.
NCT00325286 ↗ Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Unknown status Creighton University Phase 4 2006-05-01 This is an open label design using Lithium plus extended release carbamazepine (Equetro) in combination for 6 months. Rapid cycling bipolar disorder is frequently treatment refractory and associated with repeated hospitalizations and complications. The results of this study will offer a promising approach to treat this complex disorder. The primary efficacy measure will be the time to relapse. Relapse will determined by the investigator based on the following: Need for additional pharmacotherapy for mood-related symptoms, hospitalization for an mood episode, increase of more than 50% in HAM-D and YMRS scores from the baseline visit.
NCT02623504 ↗ DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting Validus Pharmaceuticals Phase 4 2016-01-01 A phase 4 unequal randomization, double blind study to evaluate the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an Open label and long term maintenance treatment in children and adolescents aged 10-17 years diagnosed with acute manic or mixed Bipolar I Disorder
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EQUETRO

Condition Name

Condition Name for EQUETRO
Intervention Trials
Bipolar Disorder 3
Mania 1
Bipolar Depression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EQUETRO
Intervention Trials
Bipolar Disorder 4
Disease 3
Depressive Disorder 1
Depression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EQUETRO

Trials by Country

Trials by Country for EQUETRO
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for EQUETRO
Location Trials
Missouri 1
Maryland 1
Florida 1
Nebraska 1
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EQUETRO

Clinical Trial Phase

Clinical Trial Phase for EQUETRO
Clinical Trial Phase Trials
Phase 4 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EQUETRO
Clinical Trial Phase Trials
Completed 2
Recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EQUETRO

Sponsor Name

Sponsor Name for EQUETRO
Sponsor Trials
Shire 3
Massachusetts General Hospital 1
Tuscaloosa Research & Education Advancement Corporation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EQUETRO
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.